Corvus Pharmaceuticals Inc

CRVS is consolidating in a Stage 4 base at the rising trendline and 200-SMA, offering medium-term bullish skew near support. However, EMAs are tightly clustered with a recent 9/20 crossover and RSI is neutral, indicating no clear short-term edge. Patience is warranted: defer engagement until a deeper pullback into the trendline/200-SMA zone is tested and accepted before committing.

• ↑Cash $215.2 M (up from $56.8 M) funds ops through Q2 2028
• ↑R&D spend up 103% YoY to $16 M signals strong trial backing
• ↓Q2 net loss $18 M vs $8 M year-ago strains cash flow